Ascites Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis

DelveInsight's "Ascites Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ascites.

DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Ascites market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ascites Market Forecast

 

Some of the key facts of the Ascites Market Report: 

• The Ascites market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• DelveInsight estimates that there were 242,201 occurrences of ascites caused by cirrhosis in the 7MM population in 2021. These cases are anticipated to rise at a respectable CAGR from 2019 to 2032, according to estimations from DelveInsight
• There were over 150,291 occurrences of ascites caused by cirrhosis in the US in 2021. According to the malignancy, there were 8,683, 3,621, 12,820, and 10,454 instances of ascites from ovarian, stomach, breast, and colorectal cancer in the US in 2021, respectively
• Ascites caused by cirrhosis is estimated to have occurred in 20,104 instances in Germany in 2021. Ascites cases related to ovarian, stomach, breast, and colorectal cancer were reported to be 5,009, 1,914, 3,495, and 3,888 in Germany in 2021, respectively
• Key Ascites Companies: BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis, BioVie Inc., Otsuka Beijing Research Institute, Jiangsu Simcere Pharma, Ocelot Bio, Inc., and others
• Key Ascites Therapies: BIV201 (Terlipressin), OCE-205, aflibercept, catumaxomab, Albutein, M0002, satavaptan (SR121463B), BIV201, Tolvaptan, Endostar, OCE-205, and others
• The Ascites epidemiology based on type-specific cases analyzed that there were 26,841 and 122,277 cases of Grade I and Grade II and III ascites due to cirrhosis in the United States
• The Ascites market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics.

 

Ascites Overview

A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. If ascites is bad, it could hurt.

 

Get a Free sample for the Ascites Market Report 

https://www.delveinsight.com/report-store/ascites-market

 

Ascites Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ascites Epidemiology Segmentation:

The Ascites market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Ascites
• Prevalent Cases of Ascites by severity
• Gender-specific Prevalence of Ascites
• Diagnosed Cases of Episodic and Chronic Ascites

 

Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast

 

Ascites Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ascites Therapies and Key Companies

• BIV201 (Terlipressin): BioVie
• OCE-205: Ocelot Bio
• aflibercept: Sanofi
• catumaxomab: Neovii Biotech
• Albutein: Grifols Therapeutics
• M0002: Movetis
• satavaptan (SR121463B): Sanofi
• BIV201: BioVie Inc.
• Tolvaptan: Otsuka Beijing Research Institute
• Satavaptan: Sanofi
• Endostar: Jiangsu Simcere Pharma
• OCE-205: Ocelot Bio, Inc

 

Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market

 

Ascites Market Strengths

• The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase inthe patient population of ascites

 

Ascites Market Opportunities

• Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies

 

Scope of the Ascites Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ascites Companies: BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis, BioVie Inc., Otsuka Beijing Research Institute, Jiangsu Simcere Pharma, Ocelot Bio, Inc., and others
• Key Ascites Therapies: BIV201 (Terlipressin), OCE-205, aflibercept, catumaxomab, Albutein, M0002, satavaptan (SR121463B), BIV201, Tolvaptan, Endostar, OCE-205, and others
• Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies
• Ascites Market Dynamics: Ascites market drivers and Ascites market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement 

 

To know more about Ascites companies working in the treatment market, visit @ Ascites Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Ascites Market Report Introduction

2. Executive Summary for Ascites

3. SWOT analysis of Ascites

4. Ascites Patient Share (%) Overview at a Glance

5. Ascites Market Overview at a Glance

6. Ascites Disease Background and Overview

7. Ascites Epidemiology and Patient Population

8. Country-Specific Patient Population of Ascites 

9. Ascites Current Treatment and Medical Practices

10. Ascites Unmet Needs

11. Ascites Emerging Therapies

12. Ascites Market Outlook

13. Country-Wise Ascites Market Analysis (2019–2032)

14. Ascites Market Access and Reimbursement of Therapies

15. Ascites Market Drivers

16. Ascites Market Barriers

17.  Ascites Appendix

18. Ascites Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Exploring the HER2-Negative Breast Cancer Promising Pipeline Therapies: An In-depth Report | Companies- AstraZeneca, Laekna, Novartis, Roche, Olema Pharma, Haihe Biopharma, G1 Therapeutics, and Others

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including HER2-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the HER2-Negative Breast Cancer Pipeline treatment landscape of the report, click here @ HER2-Negative Breast Cancer Pipeline Outlook

 

HER2-Negative Breast Cancer Overview

HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors. Common therapies for the treatment of HER2-Negative Breast Cancer include endocrine therapy (ET), ovarian suppression, aromatase inhibition, and/or CDK4/6 inhibitors.

 

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

• DelveInsight’s HER2-Negative Breast Cancer Pipeline report depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2-Negative Breast Cancer.
• The leading HER2-Negative Breast Cancer Companies include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others
• Promising HER2-Negative Breast Cancer Pipeline Therapies include AZD9833, Anastrozole, Sorafenib (Nexavar, BAY43-9006), Capecitabine, AZD9833, Ipatasertib, Paclitaxel, letrozole, Zoledronic acid, bevacizumab, docetaxel, and others
• Sacituzumab Govitecan (Gilead) is being evaluated in Phase III for Hormone receptor–positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer. Trodelvy (sacituzumab govitecan-hziy) is a first-inclass antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including metastatic triple-negative breast cancer (TNBC), where high expression is associated with poor survival and relapse. Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2- negative (HR+/HER 2−) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. Trodelvy + checkpoint inhibitor combination is also being evaluated by Gilead in a Phase Ib/II clinical trial for metastatic triple-negative breast cancer (1L).
• RG6171/ GDC-9545 (Hoffmann-La Roche) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A Phase II clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative 2/3L metastatic breast cancer. Company is expecting to file this product in 2022.
• Elacestrant/RAD1901 (Radius Pharmaceuticals) is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group, which is being evaluated for potential use as a once-daily oral treatment for HR+ breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies to treat breast cancer. In 2018, the company initiated and opened for enrollment a phase III study (EMERALD) evaluating elacestrant as second- or third-line monotherapy in postmenopausal women with advanced/metastatic estrogen receptor–positive (ER+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer patients. The study achieved its enrollment target of 466 patients who have received prior treatment with one or two lines of endocrine therapy, including a cyclin-dependent kinase (CDK) 4/6 inhibitor. In October 2021, the Radius and Menarini group jointly announced positive topline results from the EMERALD trial.

 

For further information, refer to the detailed HER2-Negative Breast Cancer Unmet Needs, HER2-Negative Breast Cancer Market Drivers, and HER2-Negative Breast Cancer Market Barriers, click here for HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis

 

HER2-Negative Breast Cancer Emerging Drugs Profile

 

• Capivasertib + Fulvestrant: AstraZeneca

Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

 

• Dalpiciclib: Jiangsu HengRui Medicine

Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.

 

Request a sample and discover the recent advances in HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ HER2-Negative Breast Cancer Treatment Landscape

 

HER2-Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 85+ HER2-Negative Breast Cancer companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

 

Dive deep into rich insights for drugs for HER2-Negative Breast Cancer Pipeline, click here @ HER2-Negative Breast Cancer Unmet Needs and Analyst Views

 

Scope of the HER2-Negative Breast Cancer Pipeline Report

• Coverage- Global
• HER2-Negative Breast Cancer Companies- include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others
• HER2-Negative Breast Cancer Pipeline Therapies- AZD9833, Anastrozole, Sorafenib (Nexavar, BAY43-9006), Capecitabine, AZD9833, Ipatasertib, Paclitaxel, letrozole, Zoledronic acid, bevacizumab, docetaxel, and others
• HER2-Negative Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on HER2-Negative Breast Cancer Mergers and acquisitions, HER2-Negative Breast Cancer Licensing Activities @ HER2-Negative Breast Cancer Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. HER2-Negative Breast Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Capivasertib + Fulvestrant: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Inavolisib: Roche
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Afuresertib + Fulvestrant: Laekna
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. HER2-Negative Breast Cancer Key Companies
23. HER2-Negative Breast Cancer Key Products
24. HER2-Negative Breast Cancer- Unmet Needs
25. HER2-Negative Breast Cancer- Market Drivers and Barriers
26. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
27. HER2-Negative Breast Cancer Analyst Views
28. HER2-Negative Breast Cancer Key Companies
29. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

The Adventures of Veggieman: Food Fight by Karla Farach is a Revolutionary Children’s Book that Promotes Healthy Eating for Kids

Written in the form of a superhero adventure for kids, Karla Farach's The Adventures of Veggieman: Food Fight! promotes a positive relationship with food for the whole family. The book recently became a #1 Amazon Bestseller.

The Adventures of Veggieman: Food Fight! is an interactive adventure for kids that makes healthy eating fun. When Niko starts a new school, he has no idea he’s about to get caught up in an epic battle between the power of good, nourishing food and evil junk food. But, with the help of superhero Veggieman and his powerful army of fruits and vegetables, Niko discovers how to unlock his inner superpower—choice. Written by award-winning, bestselling author and nutrition expert, Karla Farach, The Adventures of Veggieman: Food Fight! empowers young readers to say no to harmful junk food, and yes to healthy foods that nourish their bodies and minds.

“When I gave birth to my sons, I became aware of the widespread problem we have with how children are fed and the terrible access to junk food. Children and adults are consuming a rich-calorie and low-nutrient diet day in and day out, which has a negative effect on children’s growing bodies and brains,” says author Karla Farach. As the CEO of Mothers of Health LLC and a certified health and life coach, she was inspired to write a book that would help families adopt a healthier lifestyle. Farach specializes in writing empowering stories that spark a child's imagination and focus on consuming healthy, natural foods. She serves as a real-life example of the positive actions we can all take to build a better society—and a better world. “If children knew the effect junk food had on their wellbeing, they would be able to make educated choices. Children understand more than we think!”

Unhealthy eating is a condition that affects the whole human race—but that can change if we have the courage to move toward our collective transformation. Fun and exciting, The Adventures of Veggieman: Food Fight! is an engaging book that directly addresses the importance of eating nutritious food from an age-appropriate perspective. This creates a safe space for children to feel confident making healthier food choices. Parents, educators, and health professionals will love reading this story aloud over and over again, appreciating the positive messages and ideas, and children will have their minds filled with new possibilities of how wonderful life can be when we nourish our minds and bodies.

The Adventures of Veggieman: Food Fight! has received positive reviews from well-renowned experts, authors, and reviewers around the world. Book Excellence writes, “An enchanting tale of one lone school child and his superpower: choice, teaching children that their choices can change their lives, as well as the world around them.” In addition, an Amazon Reviewer writes, “It makes healthy eating feel exciting and accessible to kids, and less like a punishment or restriction. This should be a staple book in your home library, classroom libraries, doctor’s offices.”

Perfect for children ages 6-9, The Adventures of Veggieman: Food Fight! is a memorable read that will help every child learn to use their own superpower of choice to adopt healthy eating habits. The Adventures of Veggieman: Food Fight! is available for sale on Amazon, Barnes & Noble, other online bookstores and can be purchased here: https://www.amazon.com/Adventures-Veggieman-Food-Fight-ebook/dp/B0C457VDBK/

Readers, parents, educators and book clubs are encouraged to visit the author’s website for more information about the book and updates about new book releases: www.veggieman.com

About the Author

Karla Farach is the CEO of Mothers of Health, LLC, a company she founded to inspire women and mothers to adopt a healthier lifestyle. She is passionate about nutrition and wellness and is certified as a health and life coach by the Institute of Integrative Nutrition. Karla was born and raised in the Dominican Republic and lives in Greenwich, Connecticut, with her husband and two sons. Karla’s favorite vegetable is kale.

Connect with Karla Farach on Social Media

Facebook: https://www.facebook.com/VeggiemanKids

Instagram: https://www.instagram.com/Veggieman_kids/

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email:Send Email
Country: United States
Website: authornewsnetwork.com

Acute Ischemic Stroke Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Genentech, Inc., NoNO Inc

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Ischemic Stroke pipeline constitutes 35+ key companies continuously working towards developing 35+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Acute Ischemic Stroke Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.

 

Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years. 
• Acute Ischemic Stroke companies working in the treatment market are Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme Bio Technology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, Genentech, and others, are developing therapies for the Acute Ischemic Stroke treatment 
• Emerging Acute Ischemic Stroke therapies such as - ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS-007), 3K3A-APC, Nerinetide, Nelonemdaz, Tenecteplase, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.   
• In February 2022 A Phase II, two-part, double-blind, randomised, placebo-controlled trial was started by Lumosa Therapeutics Co., Ltd. to assess the safety and effectiveness of the LT3001 medicinal product in patients having endovascular thrombectomy (EVT) for acute ischemic stroke (AIS). When necessary, subjects who take part in this experiment should receive standard of care (SoC) AIS therapy. 66 people are now participating in the study, which is expected to be finished by April 2024
• In May 2022, "Randomization to Endovascular Treatment Alone orPreceded by Systemic Thrombolysis with Tenecteplase in Acute Ischemic Stroke Due to Large Intracranial Vessel Occlusion Trial- DIRECT Thrombectomy vs. Intravenous TNK plus Thrombectomy" is the name of the study that Boehringer Ingelheim started
• In July 2022, The European Medicines Agency (EMA) granted "PRIority Medicines" designation to ACTICOR BIOTECH for its therapeutic candidate, glenzocimab, for the treatment of stroke victims.With early conversations with regulatory agencies and stronger engagement as a result of this status, Acticor Biotech was able to confirm the clinical development strategy for the treatment of stroke with glenzocimab
• In July 2022, In a groundbreaking preclinical study, the University of Cincinnati and Case Western Reserve University (CWRU) showed that NervGen's proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was started up to 7 days after onset. This information was released by NervGen Pharma
• In June 2021, A Phase III Multi-center, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Evaluate the Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients with Acute Ischemic Stroke within 4.5 Hours after Stroke Onset was started by Boehringer Ingelheim

 

Acute Ischemic Stroke Overview

There is some overlap in risk factors and clinical presentation between ischemic and hemorrhagic acute stroke, and each requires fundamentally different care. It is a medical emergency brought on by the brain's decreasing blood supply, which damages brain cells.

 

Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight

 

Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

• ST-01: Saillant Therapeutics
• AVLX 144: Avilex Pharma
• NTS-104: NeuroTrauma Science
• PP-007: Prolong Pharmaceutical
• UMSC01: Ever Supreme Bio Technology
• NCS-01: NC Medical Research, Inc
• LT3001: Lumosa Therapeutics Co., Ltd.
• NONO-SC: NoNO Inc.
• RNS60: Revalesio Corporation
• BIIB131 (TMS-007): Biogen
• 3K3A-APC: ZZ Biotech
• Nerinetide: NoNO Inc
• Nelonemdaz: GNT Pharma
• Tenecteplase: Genentech

 

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

 

Acute Ischemic Stroke Pipeline Therapeutics Assessment

• Acute Ischemic Stroke Assessment by Product Type
• Acute Ischemic Stroke By Stage and Product Type
• Acute Ischemic Stroke Assessment by Route of Administration
• Acute Ischemic Stroke By Stage and Route of Administration
• Acute Ischemic Stroke Assessment by Molecule Type
• Acute Ischemic Stroke by Stage and Molecule Type

 

DelveInsight's Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies

 

Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Acute Ischemic Stroke are - Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

 

Acute Ischemic Stroke Pipeline Analysis:

The Acute Ischemic Stroke pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Ischemic Stroke with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
• Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies

 

Acute Ischemic Stroke Pipeline Market Drivers

• Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Acute Ischemic Stroke Market.

 

Acute Ischemic Stroke Pipeline Market Barriers

• However, Challenges associated with the clinical research, challenges associated with the diagnosis of Acute Ischemic Stroke and other factors are creating obstacles in the Acute Ischemic Stroke Market growth.

 

Scope of Acute Ischemic Stroke Pipeline Drug Insight    

• Coverage: Global
• Key Acute Ischemic Stroke Companies: Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme Bio Technology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, Genentech, and others
• Key Acute Ischemic Stroke Therapies: ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS-007), 3K3A-APC, Nerinetide, Nelonemdaz, Tenecteplase, and others
• Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers 

 

Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials

 

Table of Contents

1	Acute Ischemic Stroke Report Introduction
2	Acute Ischemic Stroke Executive Summary
3	Acute Ischemic Stroke Overview
4	Acute Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment
5	Acute Ischemic Stroke Pipeline Therapeutics
6	Acute Ischemic Stroke Late Stage Products (Phase II/III)
7	Acute Ischemic Stroke Mid Stage Products (Phase II)
8	Acute Ischemic Stroke Early Stage Products (Phase I)
9	Acute Ischemic Stroke Preclinical Stage Products
10	Acute Ischemic Stroke Therapeutics Assessment
11	Acute Ischemic Stroke Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Acute Ischemic Stroke Key Companies
14	Acute Ischemic Stroke Key Products
15	Acute Ischemic Stroke Unmet Needs
16	Acute Ischemic Stroke Market Drivers and Barriers
17	Acute Ischemic Stroke Future Perspectives and Conclusion
18	Acute Ischemic Stroke Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Deep Vein Thrombosis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Bayer, Pfizer, Biocad, MinaPharm Pharmaceuticals, LEO Pharma, Agen

DelveInsight's "Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis.

DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast

 

Some of the key facts of the Deep Vein Thrombosis Market Report: 

• The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Waheed et al. (2021) estimate that there are 80 instances of DVT annually per 100,000 people, with a prevalence of lower limb DVT of 1 case per 1000 people
• The exact number of persons who suffer from deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, however the CDC (2022) estimates that as many as 900,000 people could be impacted each year in the United States
• Approximately 33% of persons with DVT/PE will experience a recurrence within 10 years, according to CDC data (2022)
• Growing healthcare awareness and rising income levels in emerging economies could hasten the expansion of the deep vein thrombosis market. People's increased awareness of cutting-edge DVT therapies is mostly due to digitalization, which has fueled the industry
• Key Deep Vein Thrombosis Companies: Anthos Therapeutics, Inc., Mercator MedSystems, Inc., Bayer, Pfizer, Biocad, MinaPharm Pharmaceuticals, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Sanofi, and others
• Key Deep Vein Thrombosis Therapies: Abelacimab, Perivascular dexamethasone, Rivaroxaban (Xarelto, BAY59-7939), Apixaban, Sodium Enoxaparine, r-Hirudin, innohep®, ThromboView, Apixaban, Warfarin, edoxaban tosylate, Idrabiotaparinux sodium, SanOrg34006, Tinzaparin, and others
• The Deep Vein Thrombosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.

 

Deep Vein Thrombosis Overview

A blood clot known as deep vein thrombosis (DVT) develops in the deep veins, commonly in the legs, but it can also happen in the arms, mesenteric, and cerebral veins. It is a symptom of venous thromboembolism disorders, which rank third among cardiovascular diseases in terms of fatalities after heart attacks and strokes.

 

Get a Free sample for the Deep Vein Thrombosis Market Report 

https://www.delveinsight.com/report-store/deep-vein-thrombosis-market

 

Deep Vein Thrombosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Deep Vein Thrombosis Epidemiology Segmentation:

The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Deep Vein Thrombosis
• Prevalent Cases of Deep Vein Thrombosis by severity
• Gender-specific Prevalence of Deep Vein Thrombosis
• Diagnosed Cases of Episodic and Chronic Deep Vein Thrombosis

 

Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast

 

Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Deep Vein Thrombosis Therapies and Key Companies

• Abelacimab: Anthos Therapeutics, Inc.
• Perivascular dexamethasone: Mercator MedSystems, Inc.
• Rivaroxaban (Xarelto, BAY59-7939): Bayer
• Apixaban: Pfizer
• Sodium Enoxaparine: Biocad
• r-Hirudin, innohep®: MinaPharm Pharmaceuticals
• ThromboView: LEO Pharma
• Apixaban: Agen Biomedical
• Warfarin: Bristol-Myers Squibb
• edoxaban tosylate: Pfizer
• Idrabiotaparinux sodium: Daiichi Sankyo, Inc.
• SanOrg34006: Sanofi
• Tinzaparin: LEO Pharma

 

Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Market

 

Deep Vein Thrombosis Market Strengths

• The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT
• Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Deep Vein Thrombosis (DVT)

 

Deep Vein Thrombosis Market Opportunities

• New therapeutic options are needed to address the unmet need for effective and curative therapies for Deep Vein Thrombosis (DVT). This has created an opportunity for key players to develop novel therapies targeted towards this indication

 

Scope of the Deep Vein Thrombosis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Deep Vein Thrombosis Companies: Anthos Therapeutics, Inc., Mercator MedSystems, Inc., Bayer, Pfizer, Biocad, MinaPharm Pharmaceuticals, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Sanofi, and others
• Key Deep Vein Thrombosis Therapies: Abelacimab, Perivascular dexamethasone, Rivaroxaban (Xarelto, BAY59-7939), Apixaban, Sodium Enoxaparine, r-Hirudin, innohep®, ThromboView, Apixaban, Warfarin, edoxaban tosylate, Idrabiotaparinux sodium, SanOrg34006, Tinzaparin, and others
• Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
• Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement 

 

To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Deep Vein Thrombosis Market Report Introduction

2. Executive Summary for Deep Vein Thrombosis

3. SWOT analysis of Deep Vein Thrombosis

4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance

5. Deep Vein Thrombosis Market Overview at a Glance

6. Deep Vein Thrombosis Disease Background and Overview

7. Deep Vein Thrombosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Deep Vein Thrombosis 

9. Deep Vein Thrombosis Current Treatment and Medical Practices

10. Deep Vein Thrombosis Unmet Needs

11. Deep Vein Thrombosis Emerging Therapies

12. Deep Vein Thrombosis Market Outlook

13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)

14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies

15. Deep Vein Thrombosis Market Drivers

16. Deep Vein Thrombosis Market Barriers

17.  Deep Vein Thrombosis Appendix

18. Deep Vein Thrombosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Alopecia Areata Pipeline | Companies - Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma

DelveInsight’s, “Alopecia Areata Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including Alopecia Areata clinical trials and nonclinical stage products. It also covers the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Alopecia Areata Pipeline treatment landscape of the report, click here @ Alopecia Areata Pipeline Outlook

 

Key Takeaways from the Alopecia Areata Pipeline Report

• DelveInsight’s Alopecia Areata Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata.
• The leading Alopecia Areata Companies include Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
• Promising Alopecia Areata Pipeline Therapies include 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others
• The US FDA has granted BTD and Fast Track Designation (FTD) to CTP-543 for the treatment of alopecia areata. Recently, the company has presented the positive results from two Phase III studies (THRIVE-AA1, THRIVE-AA2) at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Furthermore, the company intends to submit the NDA and the data fromthe THRIVE-AA1 study to the US FDA by the first half of 2023.
• PF-06651600 (Pfizer) is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. Ritlecitinib has been shown to block the activity of signaling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata. Ritlecitinib has been granted Breakthrough Therapy designation from the US FDA for the treatment of alopecia areata in September 2018. Currently, PF-06651600 is in registration phase for the treatment of alopecia areata.
• LH-8 (Legacy Healthcare SA) is an investigational topical drug. Among the actives present in Coacillium, various flavonoids, polyphenols and methylxanthines have been associated, enabling a pleiotropic mechanism (i.e., multiple targets), to simultaneously reverse immunoinflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues. Currently it is in Phase II/III, doubleblind, vehicle-controlled, randomized, multi-center trial, evaluating the efficacy and safety of Coacillium cutaneous solution in children and adolescents with moderate (25% to 50% baldness) to severe (>50%baldness) alopecia areata.

 

For further information, refer to the detailed Alopecia Areata Unmet Needs, Alopecia Areata Market Drivers, and Alopecia Areata Market Barriers, click here for Alopecia Areata Ongoing Clinical Trial Analysis

 

Alopecia Areata Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.

 

Alopecia Areata Emerging Drugs Profile

 

• Deuruxolitinib: Concert Pharmaceuticals

Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

 

• EQ101: Equillium

EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

 

• MAX 40070: Maxinovel Pharmaceuticals

MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

 

Request a sample and discover the recent advances in Alopecia Areata Ongoing Clinical Trial Analysis and Medications, click here @ Alopecia Areata Treatment Landscape

 

Alopecia Areata Pipeline Therapeutics Assessment

There are approx. 18+ Alopecia Areata companies which are developing the Alopecia Areata therapies. The Alopecia Areata companies which have their Alopecia Areata drug candidates in the most advanced stage, i.e. phase III include, Concert Pharmaceuticals.

 

Dive deep into rich insights for drugs for Alopecia Areata Market Drivers and Alopecia Areata Market Barriers, click here @ Alopecia Areata Unmet Needs and Analyst Views

 

Scope of the Alopecia Areata Pipeline Report

• Coverage- Global
• Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
• Alopecia Areata Pipeline Therapies- 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others.
• Alopecia Areata Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Alopecia Areata Mergers and acquisitions, Alopecia Areata Licensing Activities @ Alopecia Areata Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Alopecia Areata: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alopecia Areata– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Deuruxolitinib: Concert Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. EQ101: Equillium
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MAX 40070: Maxinovel Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alopecia Areata Key Companies
21. Alopecia Areata Key Products
22. Alopecia Areata- Unmet Needs
23. Alopecia Areata- Market Drivers and Barriers
24. Alopecia Areata- Future Perspectives and Conclusion
25. Alopecia Areata Analyst Views
26. Alopecia Areata Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

ProServeIT Corporation Achieves All Solutions Partner Designations in the Microsoft Cloud Partner Program.

ProServeIT Corporation is pleased to announce that they have attained Solutions Partner designations in all six of Microsoft’s business solution areas: 

• Business Applications

• Data & AI (Azure)

• Digital & App Innovation (Azure)

• Infrastructure (Azure)

• Modern Work, and

• Security

As a result of attaining these six solution area designations, ProServeIT has also been awarded a Solutions Partner for Microsoft Cloud designation, recognizing broad capabilities across the vast expanse of Microsoft cloud technologies.

“At ProServeIT, our mission is to help organizations unlock their digital future. Our values are ‘People Matter. Be Like Gumby. And Do It Right’. These Solutions Partner designations are evidence that our values – putting people first, being flexible, and doing the right things for our customers - are propelling us forward in a positive direction, and we’re able to help our customers make technology their business enabler without compromising our values,” said Eric Sugar, President of ProServeIT Corporation. 

Solutions Partner designations are awarded to Microsoft partners who have demonstrated broad technical capabilities, success in delivering technology solutions, and have achieved a minimum of 70 points out of 100 in each category measured across performance, skilling, and customer success. These designations recognize both company qualifications and certified professionals associated with the company.

In addition to the solution area designations, ProServeIT also recently achieved specialty designations in three of the business solution areas:

• Security, Specialist Cloud Security

• Modern Work, Specialist Adoption and Change Management, and

• Infrastructure Azure, Specialist Windows Server and SQL Server Migration

With these specialist designations, customers can be confident that ProServeIT has deep expertise and seasoned experience within the Security, Modern Work, and Infrastructure solution areas.

“The Microsoft Cloud Partner Program empowers partners with differentiated capabilities to create and sell solutions for customers’ specific and unique needs,” said Dan Rippey, Program Director for the Microsoft Cloud. “By achieving these new designations, ProServeIT has clearly demonstrated that they have both the skills and the experience to help our customers harness the power of new digital capabilities and expand business opportunities in the cloud.” 

Equipped with these new designations, the team at ProServeIT can better help organizations of all sizes to unlock their digital future, secure new customers, enhance the experience for existing customers, and increase their business output.

About ProServeIT Corporation 

Established in 2002, ProServeIT Corporation was one of the first Canadian Microsoft Partners to spearhead the adoption of Cloud computing. As a modern IT specialist and trusted technology advisor, ProServeIT continues to help organizations in various industries to unlock their digital future and turn technology into a true business enabler.

ProServeIT is headquartered in Oakville, Ontario, with offices in Prince Edward Island (Canada), Illinois (United States), New Mexico (United States), Paris (France), and Ho Chi Minh City in southern Vietnam.  

ProServeIT is a people-first organization, and its employees aim to live out its three core values on a daily basis: People Matter. Be Like Gumby. Do It Right.

Your success matters to us. Partner with ProServeIT and unlock your organization’s digital future.

Media Contact
Company Name: ProServeIT
Contact Person: Kristi Hedrick
Email:Send Email
Phone: 727-346-6455
Country: United States
Website: https://proserveit.com/

Prostate Cancer Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) - Estimates DelveInsight | Novartis, ESSA Pharma, Roche, Merck, AstraZeneca, Orion, Advantagene, Astellas

Delveinsight Business Research LLP

As per DelveInsight, the Prostate Cancer Market is anticipated to evolve immensely in the coming years owing to the increasing number of cases of prostate cancer, the rising number of risk factors associated with prostate cancer, growing awareness regarding prostate cancer among men, and the launch of new therapies in the market.

Moreover, the increasing research and development activities, increasing technological advancements such as the incorporation of artificial intelligence (AI) in prostate cancer diagnosis, and government and non-government initiatives for prostate cancer among others are also anticipated to contribute immensely to the Prostate Cancer Market growth.

Some of the major pharma and biotech companies in the Prostate Cancer Market include Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, and others.

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prostate Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers the emerging Prostate Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Prostate Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Prostate Cancer: An Overview

Prostate cancer begins when cells in the prostate gland—only found in males—start to grow uncontrollably. Almost all prostate cancers are adenocarcinoma. These cancers develop from the gland cells.

Some prostate cancers can grow and spread quickly, but most grow gradually. There are usually no symptoms during the early stages of cancer. However, if symptoms do appear, they usually involve one or more of the following: frequent urges to urinate, including at night, difficulty commencing and maintaining urination, blood in the urine, and painful urination, among several others symptoms.

Prostate Cancer Market Key Facts

• Prostate Cancer is the most common type of cancer found in American men after skin cancer. The American Cancer Society estimates that roughly 191,930 new cases of prostate cancer diagnosed in the United States.

• Nearly one in nine men will develop prostate cancer in their lifetime, though it is usually diagnosed after age 40. About 6 out of 10 cases are diagnosed in men aged 65 years or older; it is rare before age 40. The average age at the time of diagnosis is about 66 years.

• According to the National Cancer Institute, approximately 10–20% of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence that cancer has spread at the time of the castration-resistant diagnosis.

• According to Prostate Cancer UK, over 47,500 men are diagnosed with prostate cancer every year—i.e. 129 men every day. One in eight men will be diagnosed with prostate cancer in their lifetime.

Prostate Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Prostate Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Prostate Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Prostate Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Prostate Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Prostate Cancer Epidemiology, Segmented as -

• Total Incident Cases of Prostate Cancer in the 7MM (2019–2032)

• Stage-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032) (E.g. Localized, Regional, Distant)

• Grade-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032) (E.g. Well differentiated, poor/undifferentiated, others)

• Age-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032)

• Treatable cases of Prostate Cancer in the 7MM (2019–2032)

Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Prostate Cancer market or expected to be launched during the study period. The analysis covers the Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Prostate Cancer market with the most rapid drug uptake and the reasons behind the maximal use of the drugs. Additionally, it compares Prostate Cancer drugs based on their sale and market share.

The report also covers the Prostate Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Prostate Cancer Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/prostate-cancer-market-insight

Prostate Cancer Therapeutics Analysis

The goals of pharmacotherapy for prostate cancer are to induce remission, reduce morbidity, and prevent complications. Agents used for the treatment of prostate cancer include the following: Androgen antagonists, Gonadotropin-releasing hormone (GnRH) agonists, Bisphosphonates, Antifungal agents, Chemo-therapeutic agents, Corticosteroids, and Immunologic agents.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Prostate Cancer. Currently, Merck is leading the therapeutics market with its Prostate Cancer drug candidates in the most advanced stage of clinical development.

Prostate Cancer Companies Actively Working in the Therapeutics Market Include

Advantagene, Advaxis, Inc., Allife Medical Science and Technology, Amgen, Arvinas Inc, Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, Bayer Health Care, BeiGene, Blue Earth Diagnostics, Bracco Diagnostics, Inc, Bristol-Myers Squibb, Cancer Targeted Technology, Cardiff Oncology, Clarity Pharmaceuticals, Clovis Oncology, eFFECTOR Therapeutics, Eli Lilly and Company, Emtora Biosciences, Epizyme, ESSA Pharma, Exelixis, Fortis Therapeutics, Inc., Genmab, Genovax, Harpoon Therapeutics, Hinova pharmaceuticals, Hoffmann-La Roche, Immunomedics, Innocrin Pharmaceutical, Janssen Research & Development, LLC, Jiangsu Hengrui Medicine Co., Laekna Limited, Leap Therapeutics, Luye Pharma Group, MacroGenics, Matrix Biomed, Merck & Co, Myovant Sciences/Takeda, Novartis, Nymox Pharmaceutical, Orion Pharma, Pfizer, Plexxikon, Regeneron Pharmaceuticals, RhoVac, Sanofi, Sophiris Bio, Suzhou Kintor Pharmaceuticals, Tavanta Therapeutics, Teneobio, Inc., Tracon Pharmaceuticals Inc., Trovagene, Vaccitech, Veru Inc., Zenith Epigenetics, and many others.

Emerging and Marketed Prostate Cancer Therapies Covered in the Report Include:

• 177Lu-PSMA-617: Novartis

• EPI-7386: ESSA Pharma

• Ipatasertib (RG7440): Hoffmann-La Roche

• Keytruda: Merck Sharp & Dohme

• Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme

• ODM-208: Orion

• Pembrolizumab: Merck & Co

• ProstAtak: Advantagene

• Rubraca (Rucaparib): Clovis Oncology

• Talzoparib: Pfizer/Astellas Pharma

• ZEN 3694: Zenith Epigenetics

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Prostate Cancer Therapeutics Landscape

https://www.delveinsight.com/sample-request/prostate-cancer-market-insight

 

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Prostate Cancer Competitive Intelligence Analysis

4. Prostate Cancer Market Overview at a Glance

5. Prostate Cancer Disease Background and Overview

6. Prostate Cancer Patient Journey

7. Prostate Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Prostate Cancer Unmet Needs

10. Key Endpoints of Prostate Cancer Treatment

11. Prostate Cancer Marketed Therapies

12. Prostate Cancer Emerging Drugs and Latest Therapeutic Advances

13. Prostate Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Prostate Cancer Market Outlook (In US, EU5, and Japan)

16. Prostate Cancer Access and Reimbursement Overview

17. KOL Views on the Prostate Cancer Market

18. Prostate Cancer Market Drivers

19. Prostate Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/prostate-cancer-market-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

 

Other Trending Healthcare Reports by DelveInsight

Candidemia Market

"Candidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Candidemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Candidemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/